Weight boss? Competition for Novo Nordisk - The Economist Podcasts Recap

Podcast: The Economist Podcasts

Published: 2025-12-18

Duration: 21 minutes

Guests: Shalesh Chitnis, Lane Green, Bella King

Summary

Novo Nordisk's dominance in the weight loss drug market faces a serious challenge from Eli Lilly's new product, Zebbound, which is quickly surpassing Wegovy in sales and market share.

What Happened

Novo Nordisk had a stronghold on the weight loss drug market with its product Wegovy since its launch in 2021. However, Eli Lilly introduced a competing drug called Zebbound in 2023, which quickly gained traction and is projected to surpass Wegovy's sales.

Novo Nordisk underestimated the market demand for weight loss drugs and faced challenges in production capacity, leading to the rise of cheaper compound versions in the market. This miscalculation has significantly impacted its market value, which has plummeted by two-thirds from its peak.

The company has undergone significant leadership changes in an attempt to regain its footing. Maziar Mike Dustar was appointed as the new CEO, and the board was significantly restructured to steer the company back to its core focus areas of obesity and diabetes.

Novo Nordisk has implemented layoffs, cutting 9,000 jobs to right-size the company and focus its efforts on the competitive landscape. The company aims to transition from a traditional pharmaceutical model to behaving more like a consumer business.

There's a growing need for improved weight loss drugs that offer better quality results, such as reducing fat without significant muscle loss and minimizing side effects like nausea.

The episode also explored the evolution of slang language, with insights from Jonathan Green, a leading expert on English slang, discussing its historical context and significance as a reflection of societal changes.

Additionally, the resurgence of the British wool industry was highlighted, noting how changing demands and happier sheep due to better weather conditions have contributed to the rise in wool prices, despite the industry's long-term decline.

Key Insights